Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk adds to board of directors

Brian Daniels elected to join the board

Danish pharmaceutical firm Novo Nordisk has elected Brian Daniels as a new member of its board of directors.

He brings over 20 years of pharmaceutical management expertise to the board, having served as director of immunology at MSD and vice president of immunology then senior vice president of global development and medical affairs at Bristol-Myers Squibb.

Currently, Daniels serves as a senior advisor to the Boston Consulting Group and a venture partner for 5AM Venture Management, both of which are based in the US.

In a statement, Novo Nordisk's board of directors said it had recommended Daniels because of “his extensive experience in clinical development, medical affairs and corporate strategy across a broad range of therapeutic areas”.

Novo Nordisk also announced the re-election of Goran Ando, Jeppe Christiansen, Bruno Angelici, Sylvie Gregoire, Liz Hewitt and Mary Szela to the board of directors.

24th February 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics